NewAmsterdam Pharma (NASDAQ:NAMS) Research Coverage Started at Truist Financial

Truist Financial started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a report released on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $57.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Stifel Nicolaus lifted their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Wall Street Zen cut shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $28.94 on Wednesday. The firm has a market capitalization of $3.33 billion, a PE ratio of -16.73 and a beta of 0.04. The business has a 50 day simple moving average of $32.63 and a two-hundred day simple moving average of $33.54. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. Equities research analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the sale, the insider directly owned 69,302 shares in the company, valued at $2,099,157.58. This represents a 59.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Louis G. Lange sold 44,619 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total value of $1,357,309.98. Following the completion of the transaction, the director owned 10,360 shares of the company’s stock, valued at approximately $315,151.20. This trade represents a 81.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 1,466,933 shares of company stock worth $48,448,017. 20.84% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC boosted its position in shares of NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares during the period. Mather Group LLC. acquired a new position in NewAmsterdam Pharma in the 3rd quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in NewAmsterdam Pharma during the 3rd quarter valued at approximately $30,000. Wells Fargo & Company MN lifted its holdings in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Finally, Navalign LLC acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $46,000. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.